Giulia Brindisi1, Valentina De Vittori1, Rosalba De Nola2,3, Elia Pignataro1, Caterina Anania1, Giovanna De Castro1, Bianca Cinicola1, Alessandra Gori1, Ettore Cicinelli2, Anna Maria Zicari1. 1. Department of Maternal Infantile and Urological Sciences, Division of Pediatric Allergology and Immunology, Sapienza University of Rome, 00185 Rome, Italy. 2. Department of Biomedical Science and Human Oncology, Gynecology and Obstetrics Section, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy. 3. Department of Tissues and Organs Transplantation and Cellular Therapies, University of Bari "Aldo Moro", Piazza G. Cesare 11, 70124 Bari, Italy.
Abstract
BACKGROUND: During the lockdown period caused by the SARS-CoV-2 pandemic, we monitored via online survey the trend of allergic symptoms and the therapeutic compliance in patients followed at our center. MATERIAL AND METHODS: In June 2020, we selected children followed at the Allergy and Immunology Service of Umberto I Hospital, aged between 6 and 16 years old, diagnosed with asthma and/or rhinitis and sensitized to grass pollen or dust mite. We sent an email with 12 multiple-choice questions investigating several areas: type of disease and sensitization, recurrence of symptoms, medication use during lockdown compared to the same period of the previous year. RESULTS: The results of 82 questionnaires showed that 17.8% of patients suffered from asthma, 24.4% from rhinitis, and 57.8% from both. Within the group of asthmatic children, most of them presented an improvement of their symptoms. Likewise, with regard to allergic rhinitis, most of them reported better clinical conditions. Regarding treatment, we observed a global decrease in the use of on-demand therapies (salbutamol, nasal corticosteroid, and antihistamine) for both pathologies. In addition, there was a reduction in the use of basal therapy for asthma and rhinitis from 2019 (23.3%) to 2020 (15.5%). CONCLUSIONS: Our data show a general trend of clinical improvement and a reduction in the use of on-demand and basal therapy in allergic children during the lockdown.
BACKGROUND: During the lockdown period caused by the SARS-CoV-2 pandemic, we monitored via online survey the trend of allergic symptoms and the therapeutic compliance in patients followed at our center. MATERIAL AND METHODS: In June 2020, we selected children followed at the Allergy and Immunology Service of Umberto I Hospital, aged between 6 and 16 years old, diagnosed with asthma and/or rhinitis and sensitized to grass pollen or dust mite. We sent an email with 12 multiple-choice questions investigating several areas: type of disease and sensitization, recurrence of symptoms, medication use during lockdown compared to the same period of the previous year. RESULTS: The results of 82 questionnaires showed that 17.8% of patients suffered from asthma, 24.4% from rhinitis, and 57.8% from both. Within the group of asthmatic children, most of them presented an improvement of their symptoms. Likewise, with regard to allergic rhinitis, most of them reported better clinical conditions. Regarding treatment, we observed a global decrease in the use of on-demand therapies (salbutamol, nasal corticosteroid, and antihistamine) for both pathologies. In addition, there was a reduction in the use of basal therapy for asthma and rhinitis from 2019 (23.3%) to 2020 (15.5%). CONCLUSIONS: Our data show a general trend of clinical improvement and a reduction in the use of on-demand and basal therapy in allergicchildren during the lockdown.
Authors: Despo Ierodiakonou; Antonella Zanobetti; Brent A Coull; Steve Melly; Dirkje S Postma; H Marike Boezen; Judith M Vonk; Paul V Williams; Gail G Shapiro; Edward F McKone; Teal S Hallstrand; Jane Q Koenig; Jonathan S Schildcrout; Thomas Lumley; Anne N Fuhlbrigge; Petros Koutrakis; Joel Schwartz; Scott T Weiss; Diane R Gold Journal: J Allergy Clin Immunol Date: 2015-07-14 Impact factor: 10.793
Authors: V De Vittori; A Pacilio; L Indinnimeo; M Marazzato; G De Castro; G Brindisi; L Schiavi; M Tosca; M Duse; A Maria Zicari Journal: Allergy Asthma Proc Date: 2019-05-01 Impact factor: 2.587
Authors: Helen A Brough; Omer Kalayci; Anna Sediva; Eva Untersmayr; Daniel Munblit; Pablo Rodriguez Del Rio; Marta Vazquez-Ortiz; Stefania Arasi; Montserrat Alvaro-Lozano; Sophia Tsabouri; Elena Galli; Burcin Beken; Philippe A Eigenmann Journal: Pediatr Allergy Immunol Date: 2020-05-31 Impact factor: 5.464
Authors: Fabio Cardinale; Giorgio Ciprandi; Salvatore Barberi; Roberto Bernardini; Carlo Caffarelli; Mauro Calvani; Giovanni Cavagni; Elena Galli; Domenico Minasi; Michele Miraglia Del Giudice; Viviana Moschese; Elio Novembre; Francesco Paravati; Diego G Peroni; Maria Angela Tosca; Giovanni Traina; Salvatore Tripodi; Gian Luigi Marseglia Journal: Ital J Pediatr Date: 2020-06-16 Impact factor: 2.638
Authors: Lucia Diaferio; Giuseppe Fabio Parisi; Giulia Brindisi; Cristiana Indolfi; Giuseppe Marchese; Daniele Giovanni Ghiglioni; Anna Maria Zicari; Gian Luigi Marseglia; Michele Miraglia Del Giudice Journal: Ital J Pediatr Date: 2020-10-06 Impact factor: 2.638
Authors: Giulia Brindisi; Anna Maria Zicari; Giuseppe Fabio Parisi; Lucia Diaferio; Cristiana Indolfi; Giuseppe Marchese; Daniele Giovanni Ghiglioni; Giuseppina Rosaria Umano; Angela Klain; Gian Luigi Marseglia; Michele Miraglia Del Giudice Journal: Ital J Pediatr Date: 2022-01-06 Impact factor: 2.638
Authors: Marilyn Urrutia-Pereira; Herberto Jose Chong-Neto; Isabella Annesi Maesano; Ignacio J Ansotegui; Luis Caraballo; Lorenzo Cecchi; Carmen Galán; Juan Felipe López; Margarita Murrieta Aguttes; David Peden; Anna Pomés; Josefina Zakzuk; Nelson A Rosário Filho; Gennaro D'Amato Journal: World Allergy Organ J Date: 2022-08-08 Impact factor: 5.516